AU2013362878B2 - Treatment of diseases involving mucin - Google Patents

Treatment of diseases involving mucin Download PDF

Info

Publication number
AU2013362878B2
AU2013362878B2 AU2013362878A AU2013362878A AU2013362878B2 AU 2013362878 B2 AU2013362878 B2 AU 2013362878B2 AU 2013362878 A AU2013362878 A AU 2013362878A AU 2013362878 A AU2013362878 A AU 2013362878A AU 2013362878 B2 AU2013362878 B2 AU 2013362878B2
Authority
AU
Australia
Prior art keywords
cancer
agent
pharmaceutically acceptable
solvate
mucin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013362878A
Other languages
English (en)
Other versions
AU2013362878A1 (en
Inventor
Javed AKHTER
Roger Aston
David L. Morris
Krishna Pillai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewSouth Innovations Pty Ltd
Original Assignee
NewSouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012905519A external-priority patent/AU2012905519A0/en
Application filed by NewSouth Innovations Pty Ltd filed Critical NewSouth Innovations Pty Ltd
Priority to AU2013362878A priority Critical patent/AU2013362878B2/en
Publication of AU2013362878A1 publication Critical patent/AU2013362878A1/en
Assigned to NEWSOUTH INNOVATIONS PTY LIMITED reassignment NEWSOUTH INNOVATIONS PTY LIMITED Request for Assignment Assignors: PITNEY PHARMACEUTICALS PTY LIMITED
Application granted granted Critical
Publication of AU2013362878B2 publication Critical patent/AU2013362878B2/en
Priority to AU2017204436A priority patent/AU2017204436B2/en
Priority to AU2019203315A priority patent/AU2019203315A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22032—Stem bromelain (3.4.22.32)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
AU2013362878A 2012-12-17 2013-12-17 Treatment of diseases involving mucin Active AU2013362878B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2013362878A AU2013362878B2 (en) 2012-12-17 2013-12-17 Treatment of diseases involving mucin
AU2017204436A AU2017204436B2 (en) 2012-12-17 2017-06-29 Treatment of diseases involving mucin
AU2019203315A AU2019203315A1 (en) 2012-12-17 2019-05-12 Treatment of diseases involving mucin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012905519A AU2012905519A0 (en) 2012-12-17 Treatment of diseases involving mucin
AU2012905519 2012-12-17
PCT/AU2013/001474 WO2014094041A1 (en) 2012-12-17 2013-12-17 Treatment of diseases involving mucin
AU2013362878A AU2013362878B2 (en) 2012-12-17 2013-12-17 Treatment of diseases involving mucin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017204436A Division AU2017204436B2 (en) 2012-12-17 2017-06-29 Treatment of diseases involving mucin

Publications (2)

Publication Number Publication Date
AU2013362878A1 AU2013362878A1 (en) 2015-06-18
AU2013362878B2 true AU2013362878B2 (en) 2017-03-30

Family

ID=50977393

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013362878A Active AU2013362878B2 (en) 2012-12-17 2013-12-17 Treatment of diseases involving mucin
AU2017204436A Active AU2017204436B2 (en) 2012-12-17 2017-06-29 Treatment of diseases involving mucin
AU2019203315A Abandoned AU2019203315A1 (en) 2012-12-17 2019-05-12 Treatment of diseases involving mucin

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017204436A Active AU2017204436B2 (en) 2012-12-17 2017-06-29 Treatment of diseases involving mucin
AU2019203315A Abandoned AU2019203315A1 (en) 2012-12-17 2019-05-12 Treatment of diseases involving mucin

Country Status (13)

Country Link
US (2) US11369666B2 (enExample)
EP (1) EP2931296B1 (enExample)
JP (1) JP6502853B2 (enExample)
KR (1) KR102255753B1 (enExample)
CN (2) CN104968358B (enExample)
AU (3) AU2013362878B2 (enExample)
CA (1) CA2895149C (enExample)
DK (1) DK2931296T3 (enExample)
ES (1) ES2727686T3 (enExample)
NZ (1) NZ631536A (enExample)
TR (1) TR201907858T4 (enExample)
WO (1) WO2014094041A1 (enExample)
ZA (1) ZA201503979B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521069A (ja) 2015-07-16 2018-08-02 プロスペクト チャーターケア アールダブリュエムシー，エルエルシー ディ／ビー／エイ ロジャー ウィリアムズ メディカル センターＰｒｏｓｐｅｃｔ Ｃｈａｒｔｅｒｃａｒｅ Ｒｗｍｃ，Ｌｌｃ Ｄ／Ｂ／Ａ Ｒｏｇｅｒ Ｗｉｌｌｉａｍｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 腹膜癌を治療するための組成物及び方法
EP3362085B1 (en) * 2015-10-14 2023-06-07 Newsouth Innovations Pty Limited Compositions for the treatment of diseases involving mucin
JPWO2017195792A1 (ja) * 2016-05-13 2019-03-14 国立大学法人 熊本大学 新規なｐｅｇ修飾酵素及びそれを用いた抗がん剤デリバリー
CN108066413A (zh) * 2016-11-15 2018-05-25 李雁 标准桃金娘油的癌性黏液溶解作用及抗肿瘤新用途
AU2019225453B2 (en) * 2018-02-23 2025-03-13 MUCPharm Pty Ltd Formulations containing mucin-affecting proteases
ES2988904T3 (es) 2019-03-07 2024-11-22 Nobo Medicine Inc Inhibidores de caspasa y métodos de utilización de los mismos
WO2021217221A1 (en) * 2020-05-01 2021-11-04 MUCPharm Pty Ltd Preventing and treating viral infections
JP2024539275A (ja) * 2021-10-27 2024-10-28 エムユーシーファーム ピーティーワイ リミテッド 呼吸器疾患を治療するための方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517832B1 (en) * 2001-08-24 2003-02-11 Jeffrey L. Marrongelle Formulations and methods for treating chronic migraine
US20080075710A1 (en) * 2006-09-25 2008-03-27 Liquid Potions Llc Herbal composition for treating hangovers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
DE4302060A1 (de) * 1993-01-26 1994-07-28 Mucos Pharma Gmbh & Co Verwendung von Bromelain zur Krebstherapie und/oder Metastasen-Prophylaxe
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH08337532A (ja) * 1995-06-14 1996-12-24 Takeda Chem Ind Ltd 医薬組成物
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CH695414A5 (de) * 2001-05-30 2006-05-15 Guenter Holzner Kosmetische Präparate gegen die Alterung der menschlichen Haut in einer Mehrkammer-Mischpackung.
AU2004294986B2 (en) * 2003-11-26 2010-09-09 Hill's Pet Nutrition, Inc. Method to reduce stool odor of companion animals
CA2522152A1 (en) * 2004-10-07 2006-04-07 Kabushiki Kaisha Sangi Transdermal and transmucosal preparations
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20100166726A1 (en) * 2007-03-07 2010-07-01 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
TWI461193B (zh) * 2009-07-24 2014-11-21 Taipei Veterans General Hospital 水飛薊或水飛薊賓用於治療神經受損之用途
JP5614978B2 (ja) * 2009-12-22 2014-10-29 独立行政法人農業・食品産業技術総合研究機構 穀物由来のプロアントシアニジン含有抽出物、及びその製造方法
CN103285383B (zh) * 2013-06-03 2015-01-07 海南通用同盟药业有限公司 一种包含菠萝蛋白酶的药物组合物及菠萝蛋白酶肠溶片

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517832B1 (en) * 2001-08-24 2003-02-11 Jeffrey L. Marrongelle Formulations and methods for treating chronic migraine
US20080075710A1 (en) * 2006-09-25 2008-03-27 Liquid Potions Llc Herbal composition for treating hangovers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEVENSON, S.M. et al., "Chemical debridement of burns: mercaptans", J. Trauma, 1981 Aug; Vol. 21, no. 8, pp 632-644. *

Also Published As

Publication number Publication date
CN116077631A (zh) 2023-05-09
CN104968358B (zh) 2022-11-18
US20220401529A1 (en) 2022-12-22
AU2017204436B2 (en) 2019-05-30
KR20150096445A (ko) 2015-08-24
EP2931296A4 (en) 2016-08-10
ZA201503979B (en) 2017-11-29
JP6502853B2 (ja) 2019-04-17
EP2931296A1 (en) 2015-10-21
JP2016502981A (ja) 2016-02-01
AU2013362878A1 (en) 2015-06-18
NZ631536A (en) 2016-12-23
CA2895149C (en) 2023-08-22
AU2019203315A1 (en) 2019-05-30
CN104968358A (zh) 2015-10-07
TR201907858T4 (tr) 2019-06-21
ES2727686T3 (es) 2019-10-17
HK1211213A1 (en) 2016-05-20
WO2014094041A1 (en) 2014-06-26
EP2931296B1 (en) 2019-02-27
DK2931296T3 (da) 2019-06-03
KR102255753B1 (ko) 2021-05-26
US20150343035A1 (en) 2015-12-03
US11369666B2 (en) 2022-06-28
AU2017204436A1 (en) 2017-07-20
CA2895149A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
US20220401529A1 (en) Treatment of diseases involving mucin
US20160228399A1 (en) Pharmaceutical combinations for the treatment of cancer
JP6483736B2 (ja) 癌の治療のためのキナーゼ阻害剤
JP5457196B2 (ja) Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ
AU2016340017B2 (en) Compositions and methods for the treatment of diseases involving mucin
HK1211213B (en) Treatment of diseases involving mucin
CN108403701A (zh) 二氢雷公藤红素在制备预防或治疗血液肿瘤疾病的药物中的用途
HK1222548B (en) Pharmaceutical combinations for the treatment of cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEWSOUTH INNOVATIONS PTY LIMITED

Free format text: FORMER APPLICANT(S): PITNEY PHARMACEUTICALS PTY LIMITED

FGA Letters patent sealed or granted (standard patent)